Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 618-626

  Jastrzebski, Sandra ^a   Kalinowski, Judith ^a   Stolina, Marina ^b   Mirza, Faryal ^a   Torreggiani, Elena ^a   Kalajzic, Ivo ^a   Won, Hee Yeon ^a   Lee, Sun Kyeong ^a   Lorenzo, Joseph ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

BONE; OSTEOCYTE; OVARIECTOMY; SCLEROSTIN; SERUM

Indexed keywords

DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; SCLEROSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALVARIA; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; OVARIECTOMY;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OVARIECTOMY; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873956617     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1773     Document Type: Article

References (43)

1. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001 Mar 1; 10 (5): 537-43.
2. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J., Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001 Mar; 68 (3): 577-89.
3. Balemans W, Van Hul W., Human genetics of SOST. J Musculoskelet Neuronal Interact. 2006 Oct-Dec; 6 (4): 355-6.
4. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005 May 20; 280 (20): 19883-7.
5. Semenov M, Tamai K., He X., SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005 Jul 22; 280 (29): 26770-5.
6. Logan CY, Nusse R., The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-10.
7. Johnson ML, Harnish K, Nusse R, Van Hul W., LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res. 2004 Nov; 19 (11): 1749-57.
8. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, Lacombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML., LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23.
9. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML., A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70 (1): 11-9.
10. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP., High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346 (20): 1513-21.
11. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R., Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006 Nov; 21 (11): 1738-49.
12. Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, Zheng J, Li L, Harris S, Wu D., The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol. 2004 Jun; 24 (11): 4677-84.
13. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C., Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008 Jun; 23 (6): 860-9.
14. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. Dec 1;. 2003; 22 (23): 6267-76.
15. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002 Feb; 39 (2): 91-7.
16. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM., Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005 Jul; 15 (7): 928-35.
17. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. Nov;. 2005; 19 (13): 1842-4.
18. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ., Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012 Jan 15; 492 (1): 1-18.
19. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW., Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009 Jun; 88 (6): 569-74.
20. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN, Little CB., Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage. 2011 Jul; 19 (7): 874-85.
21. Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LE., Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep. 2011 Jun; 9 (2): 76-82.
22. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL., Melton LJ 3rd, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011 Feb; 26 (2): 373-9.
23. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL., Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005 Nov; 146 (11): 4577-83.
24. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T., Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008; 3 (8): e2942.
25. Kaji H, Imanishi Y, Sugimoto T, Seino S., Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes. 2011 Jul; 119 (7): 440-4.
26. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP., Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab. 2011 Dec; 96 (12): 3804-10.
27. Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH., Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2012 Jun; 23 (6): 1789-97.
28. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ., Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab. 2011 Nov; 96 (11): E1848-51.
29. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA., Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010 Apr; 95 (4): 1991-7.
30. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S., Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011 Jan; 26 (1): 27-34.
31. Mödder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S., Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone. 2011 Aug; 49 (2): 202-7.
32. Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, Lee SK, Lorenzo JA, Kim GS, Koh JM., Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int. 2012 Apr; 23 (4): 1235-43.
33. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
34. Halleux C, Kramer I, Allard C, Kneissel M., Isolation of mouse osteocytes using cell fractionation for gene expression analysis. Methods Mol Biol. 2012; 816: 55-66.
35. Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA., Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res. 2006; 21 (5): 695-702.
36. Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, Gronowicz G, Adams DJ, Aguila HL, Choi Y, Lorenzo JA., T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res. 2006; 21 (11): 1704-12.
37. Shahnazari M, Dwyer D, Chu V, Asuncion F, Stolina M, Ominsky M, Kostenuik P, Halloran B., Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone. 2012 Mar; 50 (3): 628-37.
38. Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T., Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012 Jan; 50 (1): 209-17.
39. Bonewald LF., The amazing osteocyte. J Bone Miner Res. 2011 Feb; 26 (2): 229-38.
40. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose placebo-controlled, randomized study of AMG 785: a sclerostin monoclonal antibody. J Bone Miner Res. 2011 Jan; 26 (1): 19-26.
41. Rachner TD, Khosla S, Hofbauer LC., Osteoporosis: now and the future. Lancet. 2011 Apr 9; 377 (9773): 1276-87.
42. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH., Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011 Dec; 26 (12): 2812-22.
43. Khosla S, Melton LJJ3rd, Riggs BL., The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res. 2011 Mar; 26 (3): 441-51.